Allianz SE

Critical framing note. Allianz is an insurance and asset management group, not an industrial or software company. Several of the metrics requested in a generic template — gross profit, EBITDA, capex, free cash flow, ROIC, net debt/EBITDA, asset turnover, cash conversion cycle, current ratio — are either not reported, not meaningful, or not defined for a regulated insurer under IFRS 17. Allianz does not present a gross-profit line, does not report EBITDA, and does not present a current/non-current balance sheet classification. The economically equivalent metrics for this business are operating profit, combined ratio, CSM, core RoE, Solvency II ratio, operating Solvency II capital generation, and net cash remittance to the holding company — all of which are given.

Income statement: notes and sources

FY2021 and the first FY2022 column are IAS 39/IFRS 4; the second FY2022 column is the IFRS 9/17 restatement. Non-controlling interest lines are (derived) as the difference between total and attributable net income.

Per-share data and margins: notes and sources

Payout ratios and margins are: (derived). FY2021 margins are calculated on IFRS 4 total revenues; FY2022 onward on IFRS 17 total business volume.

Growth rates and CAGRs: notes and sources

All: (derived). The 19.0% core EPS CAGR flatters the underlying franchise because FY2022 was depressed by the Structured Alpha provision. Management's own CMD framing uses FY2024 core EPS of EUR 25 as the base for a 7–9% CAGR through 2027; FY2025 delivered 12.5% headline and 10.8% adjusted, and 6M 2026 delivered 17.5% headline and ~10% adjusted — above the top of the target band.

Balance sheet: notes and sources

FY2022 is shown on both bases. The FY2021-to-FY2022 collapse in shareholders' equity from EUR 80bn to EUR 51–54bn is not an operating event: it is the mark-to-market destruction of the available-for-sale bond revaluation reserve as rates rose in 2022, compounded by the IFRS 9/17 transition. Total equity is (derived).

Total debt, short/long split, net debt, goodwill and intangibles, and working capital: not separately disclosed in the sources reviewed. These appear in the Annual Report 2025 balance sheet and notes. For an insurer, "debt" is a policy choice (senior and subordinated issuance for Solvency II tiering), not a leverage constraint in the industrial sense; the binding constraint is the Solvency II ratio, disclosed above at 218% at end-2025 and 225% at June 30, 2026 (on quarterly dividend accrual; approximately -7 points if full-year dividend accrual is applied).

Cash flow and remittance

Operating cash flow, capex, free cash flow and dividends paid in cash: not disclosed in the earnings releases reviewed — the IFRS cash flow statement is in the Annual Report 2025. For a group of this type, the operationally meaningful cash metric is net cash remittance from operating entities to Allianz SE, for which Allianz has set a cumulative 2025–2027 target of more than EUR 27bn.

Returns and efficiency ratios: notes and sources

Return on assets is: (derived). FY2022 ROA uses the IFRS 17 restated asset base. FY2021 uses the IFRS 4 base and is therefore not comparable.

ROIC, net debt/EBITDA, interest coverage, current ratio, debt-to-equity, asset turnover and cash conversion cycle: not disclosed and not meaningful metrics for a Solvency II-regulated insurance group. Allianz does not publish them, and constructing them would require assumptions that the "never fabricate" instruction forbids.

Commentary on trends, inflections and drivers

Inflection one — the 2022 trough. FY2022 was the low point of the cycle on every measure that matters: core RoE of 12.8%, shareholders' core net income of EUR 6,984mn, and a EUR 26bn destruction of book equity. Two forces converged: the Structured Alpha resolution (approximately USD 6bn, recognized largely in FY2021's non-operating result and finalized in 2022) and the bond-market repricing that erased the revaluation reserve. Nothing about the underlying underwriting franchise changed; the accounting and the legal tail did.

Inflection two — the FY2023–FY2025 P&C repricing. Hard-market pricing in commercial lines and aggressive retail rate action, combined with a decisive expense-ratio grind (24.2% to 23.9% to 23.7% in 6M 2026), took the combined ratio from 93.8% to 91.4% in two and a half years. Each point of combined ratio on roughly EUR 65bn of earned premium is worth on the order of EUR 650mn of pre-tax profit; the improvement essentially explains the entire EUR 2.1bn increase in P/C operating profit from FY2023 to FY2025.

Inflection three — the 2026 asset-management acceleration. After three years of low-single-digit operating profit growth, Asset Management posted 19.8% operating profit growth in 2Q 2026 (23% FX-adjusted) on 19.3% revenue internal growth. Third-party AuM went from EUR 1.712tn (end-2023) to EUR 2.161tn (June 2026), a 26% increase. This is the segment with the most operating leverage and the least capital intensity, and it is now the marginal driver of group earnings growth.

Structural driver — the CSM stock. The EUR 55.7bn gross / EUR 35.4bn net contractual service margin at end-2025 is the single most under-appreciated asset on the balance sheet. It is contractually earned profit that will release over decades. Normalized growth of 5.2% in FY2025 means the stock is compounding faster than it is releasing — the Life/Health business is growing its future earnings base even while its reported operating profit looks flat.

Headwind — FX. In FY2025, foreign currency translation cost the Asset Management segment EUR 170bn of third-party AuM (against EUR 139bn of net inflows and EUR 94bn of market gains) and reduced group total growth to 4.0% against 8.1% internal growth. Roughly half of Allianz's earnings are non-euro; a weak dollar is a direct translation drag.

Headwind — commercial rate softening. Commercial internal growth decelerated from 7% (FY2025) to 4% (6M 2026) to 1% (2Q 2026). The commercial combined ratio deteriorated from 90.3% (2Q 2025) to 91.8% (2Q 2026). This is the earliest visible crack in the P&C story.

Management guidance

Every disclosed segment is running ahead of its full-year outlook midpoint at the half-year mark. The FY2026 target of EUR 17.4bn is, notably, exactly the FY2025 outcome — management is guiding to flat operating profit while simultaneously guiding to 7–9% core EPS growth. The reconciliation is buy-backs, a lower share count, an improved non-operating result and mix shift toward the lower-tax, lower-minority Asset Management segment.

Consensus growth expectations

Sell-side consensus places the twelve-month target at EUR 439.22, approximately 2.5% below the September 2026 price. Goldman Sachs' published core EPS CAGR estimate of 8.5% sits at the upper-middle of the company's 7–9% band. Consensus, in short, believes the plan will be delivered and that the delivery is already in the price.

Three bull-case arguments, grounded in the data

1. The 2025–2027 targets are being beaten with two years still to run, which means the next CMD resets from a higher base. Core RoE of 20.7% annualized in 6M 2026 against a "17% plus" target. Solvency II operating capital generation of 25 points in FY2025 against a 24–25 point 2027 target. Asset management cost-income ratio of 60.3% against a ~60% 2027 target. P/C combined ratio of 91.4% against a 92–93% 2027 target. Three of five headline targets were achieved eighteen to twenty-four months early. The credible bull case is not that Allianz hits its plan — it is that the plan is now the floor, and that a 2027 Capital Markets Day resets targets from a materially higher base with a materially stronger balance sheet.

2. Asset management has inflected and is the highest-multiple earnings stream in the group. Third-party AuM went from EUR 1.635tn (FY2022) to EUR 2.161tn (June 2026). Net inflows went from EUR 85bn (FY2024) to EUR 139bn (FY2025) to EUR 84bn in six months of 2026 (+99.5% year-on-year). 2Q 2026 operating profit grew 19.8%, or 23% FX-adjusted, on 19.3% revenue internal growth — that is operating leverage of roughly 1.2x, in a business requiring no incremental capital. Pending acquisitions (UOBAM) and the PIMCO M Unit simplification both increase Allianz's clean economic interest. If this segment reaches EUR 4bn of operating profit in 2027 as targeted, it will be contributing over 21% of segment profit at a valuation multiple materially above that applied to underwriting earnings.

3. Capital return is mechanical, growing and under-appreciated. Total shareholder yield of 5.21% — a 3.80% dividend plus roughly 1.4% of buy-back — against a 75% formal payout framework, a 218% (rising to 225%) Solvency II ratio versus a 180% target and a 150% payout constraint, and EUR 25 points of annual operating capital generation. DPS has compounded at 12.2% per annum since FY2021 with a stated floor of never cutting. Approximately 45 points of Solvency II surplus above the operating floor represents very substantial excess capital that must go to shareholders, acquisitions, or both.

Three bear-case arguments, grounded in the data

1. Every commercial-lines indicator has turned, and commercial is roughly half of the P&C profit engine. Commercial internal growth: 7% (FY2025) → 4% (6M 2026) → 1% (2Q 2026). Commercial combined ratio: 90.3% (2Q 2025) → 91.8% (2Q 2026), a 1.5-point deterioration. The group loss ratio also worsened in 2Q 2026, to 68.1% from 67.4%, attributed to "prudent run-off" — which is management's language for having less reserve release available. P&C now represents 50.1% of segment operating profit, up from 45.4% two years ago, precisely because it has been the growth engine. That concentration cuts both ways in a softening market.

2. FY2025's margin was flattered by natural catastrophe luck that will not repeat, and management said so. The FY2025 loss-ratio improvement of 1.0 point was explicitly attributed to "lower natural catastrophe losses and underlying improvements from underwriting actions" that together "overcompensated a conservative run-off ratio." Strip out the catastrophe benefit and the underlying improvement is materially smaller than the headline. A normal-to-adverse catastrophe year on an unchanged expense base would take the combined ratio back toward the 92–93% guidance range, costing roughly EUR 500–700mn of operating profit — approximately 4% of group operating profit, in a year guided to be flat.

3. The valuation now requires flawless execution, and the sell-side does not see upside. The shares trade at 14.8x trailing earnings and roughly 1.4x adjusted tangible book against a consensus target of EUR 439.22 — below the current price. The stock has returned 19.9% per annum for five years and over 37% in 2025 alone, against a sector that returned 25%. That re-rating was driven by rising rates, hard P&C pricing and IFRS 17 clarity. All three are now in the base. Meanwhile, the group is contemplating a GBP 5bn acquisition of a leveraged UK roadside-assistance business carrying GBP 1.976bn of net debt at 4.1x EBITDA — an asset outside its core underwriting competence, at a price bankers expect to exceed the GBP 4bn enterprise value at which Stonepeak entered in July 2024. A stock priced for perfect execution making an out-of-competence acquisition at a full price is the classic setup for multiple compression.

Key catalysts and monitorables, next twelve months

Concluding analyst verdict

Allianz enters the second half of its 2025–2027 strategic cycle in the strongest operating and capital position in its modern history, and with a share price that reflects it. The evidence of franchise quality is unambiguous: four consecutive years of operating profit growth to a record EUR 17,374mn, a combined ratio compressed from 93.8% to 91.4%, a contractual service margin of EUR 57.3bn compounding faster than it releases, third-party assets under management at a record EUR 2.161tn on record inflows, and a Solvency II ratio of 225% against a 180% target. Three of five headline Capital Markets Day targets were achieved eighteen to twenty-four months ahead of schedule. Management has been credible, conservative in guidance and disciplined in capital allocation — the Income Insurance withdrawal, painful and public as it was, remains the single best evidence that price discipline is real rather than rhetorical.

The difficulty is that all of this is understood by the market. The shares have compounded at 19.9% per annum for five years, returned over 37% in 2025 alone, and now trade at approximately 14.8x trailing earnings and roughly 1.4x adjusted tangible book, above a consensus target of EUR 439.22. The three macro forces that drove the re-rating — normalizing rates, hard commercial pricing and IFRS 17 clarity — are all now in the base. From here, returns must come from execution, and execution faces two identifiable near-term tests: a commercial-lines market that has visibly turned on every disclosed metric, and a FY2025 margin that was partly a gift from a benign catastrophe year.

The pivotal near-term decision is the AA. A disciplined pass, or a transaction structured well below the reported GBP 5bn, would confirm that the capital-allocation framework holds under temptation. A full-price acquisition of a leveraged, non-core distribution asset would be the first serious departure from the framework that has driven the re-rating, and would likely cost the shares their premium.

Position: a high-quality, well-capitalized compounder trading close to fair value, with an approximately 5.2% total shareholder yield providing a solid floor, a credible path to 7–9% core EPS growth, and asymmetric downside risk concentrated in commercial-lines cyclicality and acquisition discipline rather than in anything structural. Own for the yield and the balance sheet; do not underwrite further multiple expansion.

APPENDIX — DATA QUALITY AND VERIFICATION NOTES

1. Not publicly disclosed, and not estimated: top-ten institutional holders and percentage stakes; PIMCO versus AllianzGI split of AuM, revenue and profit; total debt and short/long split; net debt; goodwill and intangibles; working capital; operating cash flow, capex and free cash flow; R&D spend; patent portfolio size; debt maturity schedule; individual FY2025 remuneration for Board members other than the CEO; PIMCO M Unit purchase price; Viridium, Sconset Re, Luko, TUA and several older transaction values; country-level revenue splits; group-wide diversity metrics; CDP score; Sustainalytics numerical risk score; FY2023 AM net flows.

2. Derived rather than reported, and flagged in-line: FY2023 and FY2024 segment operating profit for L/H and AM; FY2023 P/C business volume; FY2024 and FY2025 L/H business volume; Corporate and Other residuals; all CAGRs, payout ratios, margins and return-on-assets figures; segment contribution percentages; current market capitalization from price times share count.

3. Source conflicts identified: market capitalization ranges from EUR 141.6bn to EUR 183.2bn (USD) across aggregators against Allianz's own EUR 157.5bn at June 30, 2026 — differing dates, share-count conventions and currency. One outlet's EUR 93.0bn figure for September 1, 2026 is not reconcilable and should be disregarded.

4. Accounting-basis discontinuity: FY2021 and FY2022-as-originally-reported are IAS 39/IFRS 4; FY2022-restated through FY2025 are IFRS 9/IFRS 17. Any FY2021-to-FY2023-or-later comparison crosses this boundary and is not like-for-like. Both FY2022 bases are shown wherever the series spans the transition.